We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

This study has been withdrawn prior to enrollment.
(Few patients would like to participate ,since CIK cell transfusion was a new treatment and its efficacy was doubted.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01533727
First Posted: February 15, 2012
Last Update Posted: December 9, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Li Zhang, Sun Yat-sen University
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)